Startseite Copeptin – a biomarker of short-term mortality risk (7 days) in patients with end-stage liver disease
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Copeptin – a biomarker of short-term mortality risk (7 days) in patients with end-stage liver disease

  • Christoph Schneider , Johannes Remmler , Jeffrey Netto , Daniel Seehofer , Cornelius Engelmann , Thomas Berg , Joachim Thiery und Thorsten Kaiser EMAIL logo
Veröffentlicht/Copyright: 13. Juni 2019
Veröffentlichen auch Sie bei De Gruyter Brill
Manuskript einreichen Informationen für Autor*innen
Clinical Chemistry and Laboratory Medicine (CCLM)
Aus der Zeitschrift Clinical Chemistry and Laboratory Medicine (CCLM) Band 57 Heft 12

Abstract

Background

For many patients with end-stage liver disease, liver transplantation represents the only curative therapy. Transplant recipients are scored and ranked using the model for end-stage liver disease (MELD/MELD-Na). Circulatory impairment is known to deteriorate outcomes; however, it is not incorporated into the current allocation system’s score. The aim of our study is to analyze the predictive value of copeptin as a biomarker of circulatory impairment and increased short-term mortality risk in patients with end-stage liver disease.

Methods

We conducted a retrospective observational study of 615 patients with end-stage liver disease. Patients were recruited using assessments performed during the evaluation process for liver transplantation. Copeptin values were analyzed in comparison to MELD-Na, interleukin 6 (IL-6), and C-reactive protein (CRP).

Results

Elevated levels of copeptin, IL-6 and CRP, as well as high MELD-Na scores, were significantly correlated with mortality. In a comparison of copeptin-tertiles, patients in group T3 (16.3 pmol/L or more) showed a significantly higher mortality risk (hazard ratio 11.2, p < 0.001). After adjusting for MELD-Na, copeptin remains an independent predictor of mortality. It shows its greatest prognostic strength in short-term mortality, where it performs comparable to MELD-Na (AUROC for 7 day-mortality, 0.941/0.939; p = 0.981) and shows an additional predictive value to MELD-Na for short-term mortality (7 days, p: 0.046; 30 days, p: 0.006).

Conclusions

Copeptin presents a valuable individual biomarker in detecting patients at risk for short-term mortality. Further studies should be performed to confirm our findings.

Keywords: cholesterol esterification; interleukin-6 (IL-6); liver transplantation; model of end-stage liver disease (MELD) score
Corresponding author: Dr. med. Thorsten Kaiser, Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital Leipzig, Paul-List-Str. 13-15, 04103 Leipzig, Germany, Phone: +49 341 9722200, Fax: +49 341 22209
aChristoph Schneider and Johannes Remmler contributed equally to this work.

  1. Author contributions: Study concept and design: C.S., J.R., J.N., D.S., C.E., T.B., J.T., T.K.; acquisition of data: C.S., J.N.; analysis and/or interpretation of data: C.S., J.R., J.N., D.S., C.E., T.B., J.T., T.K.; statistical analysis: J.R., C.E., T.K.; drafting the manuscript: C.S., J.R., T.K.; critical revision of the manuscript for important intellectual content: C.S., J.R., J.N., D.S., C.E., T.B., J.T., T.K.; final approval of the version to be published: C.S., J.R., J.N., D.S., C.E., T.B., J.T., T.K.; study supervision: T.K. All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Wiesner RH, McDiarmid SV, Kamath PS, Edwards EB, Malinchoc M, Kremers WK, et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl 2001;7: 567–80.10.1053/jlts.2001.25879Suche in Google Scholar PubMed

2. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91–6.10.1053/gast.2003.50016Suche in Google Scholar PubMed

3. Kalra A, Wedd JP, Biggins SW. Changing prioritization for transplantation: MELD-Na, hepatocellular carcinoma exceptions, and more. Curr Opin Organ Transplant 2016;21:120–6.10.1097/MOT.0000000000000281Suche in Google Scholar PubMed

4. Cazzaniga M, Dionigi E, Gobbo G, Fioretti A, Monti V, Salerno F. The systemic inflammatory response syndrome in cirrhotic patients: Relationship with their in-hospital outcome. J Hepatol 2009;51:475–82.10.1016/j.jhep.2009.04.017Suche in Google Scholar PubMed

5. Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med 2010;362:823–32.10.1056/NEJMra0901512Suche in Google Scholar PubMed

6. Bajaj JS, O’Leary JG, Tandon P, Wong F, Garcia-Tsao G, Kamath PS, et al. Hepatic encephalopathy is associated with mortality in patients with cirrhosis independent of other extrahepatic organ failures. Clin Gastroenterol Hepatol 2017;15:565–74.e4.10.1016/j.cgh.2016.09.157Suche in Google Scholar PubMed

7. Asrani SK, Simonetto DA, Kamath PS. Acute-on-chronic liver failure. Clin Gastroenterol Hepatol 2015;13:2128–39.10.1016/j.cgh.2015.07.008Suche in Google Scholar PubMed PubMed Central

8. Jalan R, Saliba F, Pavesi M, Amoros A, Moreau R, Ginès P, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol 2014;61:1038–47.10.1016/j.jhep.2014.06.012Suche in Google Scholar PubMed

9. Battista S, Audisio U, Galluzzo C, Maggiorotto M, Masoero M, Forno D, et al. Assessment of diagnostic and prognostic role of copeptin in the clinical setting of sepsis. BioMed Res Int [Internet]. 2016;2016:3624730. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4913060/. [cited 2017 Mar 22]; 2016.10.1155/2016/3624730Suche in Google Scholar PubMed PubMed Central

10. Palmiere C, Augsburger M. Copeptin as a diagnostic biomarker for sepsis-related deaths. Peptides 2014;59:75–8.10.1016/j.peptides.2014.07.011Suche in Google Scholar PubMed

11. Morgenthaler NG, Müller B, Struck J, Bergmann A, Redl H, Christ-crain M. Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock 2007;28:219–26.10.1097/SHK.0b013e318033e5daSuche in Google Scholar PubMed

12. Yan J-J, Lu Y, Kuai Z-P, Yong Y-H. Predictive value of plasma copeptin level for the risk and mortality of heart failure: a meta-analysis. J Cell Mol Med [Internet]. Available from: http://onlinelibrary.wiley.com/doi/10.1111/jcmm.13102/full [cited 2017 Jul 30].10.1111/jcmm.13102Suche in Google Scholar PubMed PubMed Central

13. Westermann I, Dünser MW, Haas T, Jochberger S, Luckner G, Mayr VD, et al. Endogenous vasopressin and copeptin response in multiple trauma patients. Shock 2007;28:644–9.10.1097/shk.0b013e3180cab33fSuche in Google Scholar PubMed

14. Choi K-S, Cho Y, Jang B-H, Kim W, Ahn C, Lim TH, et al. Prognostic role of copeptin after traumatic brain injury: a systematic review and meta-analysis of observational studies. Am J Emerg Med 2017;35:1444–50.10.1016/j.ajem.2017.04.038Suche in Google Scholar PubMed

15. Morgenthaler NG, Struck J, Jochberger S, Dünser MW. Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab 2008;19:43–9.10.1016/j.tem.2007.11.001Suche in Google Scholar PubMed

16. Baumann G, Dingman JF. Distribution, blood transport, and degradation of antidiuretic hormone in man. J Clin Invest 1976;57:1109–16.10.1172/JCI108377Suche in Google Scholar PubMed PubMed Central

17. Fenske WK, Schnyder I, Koch G, Walti C, Pfister M, Kopp P, et al. Release and decay kinetics of copeptin versus AVP in response to osmotic alterations in healthy volunteers. J Clin Endocrinol Metab 2017;103:505–13.10.1210/jc.2017-01891Suche in Google Scholar PubMed

18. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151–7.10.1002/hep.1840080532Suche in Google Scholar PubMed

19. Prin M, Bakker J, Wagener G. Hepatosplanchnic circulation in cirrhosis and sepsis. World J Gastroenterol 2015;21:2582–92.10.3748/wjg.v21.i9.2582Suche in Google Scholar PubMed PubMed Central

20. United Network for Organ Sharing (UNOS). Policy notice 11/2015: OPTN executive committee actions. Available at: https://optn.transplant.hrsa.gov/media/1575/policynotice_20151101.pdf. Accessed: November 31, 2017.Suche in Google Scholar

21. Pinzani M, Rosselli M, Zuckermann M. Liver cirrhosis. Best Pract Res Clin Gastroenterol 2011;25:281–90.10.1016/j.bpg.2011.02.009Suche in Google Scholar PubMed

22. Møller S, Henriksen JH. Cardiovascular complications of cirrhosis. Gut 2008;57:268–78.10.1136/gut.2006.112177Suche in Google Scholar PubMed

23. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: From the patient to the molecule. Hepatology 2006;43(S1):S121–31.10.1002/hep.20993Suche in Google Scholar PubMed

24. Bolognesi M, Pascoli MD, Verardo A, Gatta A. Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis. World J Gastroenterol 2014;20:2555–63.10.3748/wjg.v20.i10.2555Suche in Google Scholar PubMed PubMed Central

25. Cervoni J-P, Thévenot T, Weil D, Muel E, Barbot O, Sheppard F, et al. C-reactive protein predicts short-term mortality in patients with cirrhosis. J Hepatol 2012;56:1299–304.10.1016/j.jhep.2011.12.030Suche in Google Scholar PubMed

26. Cervoni J, Amorós À, Bañares R, Montero JL, Soriano G, Weil D, et al. Prognostic value of C-reactive protein in cirrhosis: external validation from the CANONIC cohort. Eur J Gastroenterol Hepatol 2016;28:1028–34.10.1097/MEG.0000000000000676Suche in Google Scholar PubMed

27. Remmler J, Schneider C, Treuner-Kaueroff T, Bartels M, Seehofer D, Scholz M, et al. Increased level of interleukin 6 associates with increased 90-day and 1-year mortality in patients with end-stage liver disease. Clin Gastroenterol Hepatol 2018;16:730–7.10.1016/j.cgh.2017.09.017Suche in Google Scholar PubMed

28. Moreno J-P, Grandclement E, Monnet E, Clerc B, Agin A, Cervoni J-P, et al. Plasma copeptin, a possible prognostic marker in cirrhosis. Liver Int 2013;33:843–51.10.1111/liv.12175Suche in Google Scholar PubMed

29. Solà E, Kerbert AJ, Verspaget HW, Moreira R, Pose E, Ruiz P, et al. Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis. J Hepatol 2016;65:914–20.10.1016/j.jhep.2016.07.003Suche in Google Scholar PubMed

30. Kerbert AJ, Verspaget HW, Navarro ÀA, Jalan R, Solà E, Benten D, et al. Copeptin in acute decompensation of liver cirrhosis: relationship with acute-on-chronic liver failure and short-term survival. Crit Care 2017;21:321.10.1186/s13054-017-1894-8Suche in Google Scholar PubMed PubMed Central

Supplementary Material

The online version of this article offers supplementary material (https://doi.org/10.1515/cclm-2019-0023).

Received: 2019-01-07
Accepted: 2019-05-09
Published Online: 2019-06-13
Published in Print: 2019-11-26

© 2019 Walter de Gruyter GmbH, Berlin/Boston

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. The re-emergence of dried blood spot sampling – are we ready?
  4. Review
  5. The role of platelets in bleeding in patients with thrombocytopenia and hematological disease
  6. Opinion Paper
  7. Exertional hematuria: definition, epidemiology, diagnostic and clinical considerations
  8. Guidelines and Recommendations from Scientific Societies
  9. A protocol for testing the stability of biochemical analytes. Technical document
  10. Genetics and Molecular Diagnostics
  11. Hereditary hyperferritinaemia-cataract syndrome (HHCS) – an underestimated condition: ferritin light chain variant spectrum in German families
  12. General Clinical Chemistry and Laboratory Medicine
  13. Performance of a web-based application measuring spot quality in dried blood spot sampling
  14. Clinical application of a dried blood spot assay for sirolimus and everolimus in transplant patients
  15. Plasma and dried blood spot lysosphingolipids for the diagnosis of different sphingolipidoses: a comparative study
  16. Liquid biopsy of cerebrospinal fluid identifies neuronal pentraxin receptor (NPTXR) as a biomarker of progression of Alzheimer’s disease
  17. Integrity of serum samples is changed by modified centrifugation conditions
  18. Heparin and citrate additive carryover during blood collection
  19. Copeptin – a biomarker of short-term mortality risk (7 days) in patients with end-stage liver disease
  20. Comparison of a new rapid method for the determination of adalimumab serum levels with two established ELISA kits
  21. Measurement of α-dicarbonyl compounds in human saliva by pre-column derivatization HPLC
  22. Establishment of the intelligent verification criteria for a routine urinalysis analyzer in a multi-center study
  23. Reference Values and Biological Variations
  24. A new indirect estimation of reference intervals: truncated minimum chi-square (TMC) approach
  25. EGFR and EGFR ligands in serum in healthy women; reference intervals and age dependency
  26. Early pregnancy reference intervals; 29 serum analytes from 4 to 12 weeks’ gestation in naturally conceived and uncomplicated pregnancies resulting in live births
  27. Paediatric reference intervals for 17 Roche cobas 8000 e602 immunoassays in the CALIPER cohort of healthy children and adolescents
  28. Hematology and Coagulation
  29. Study of the analytical performance at different concentrations of hematological parameters using Spanish EQAS data
  30. Multicenter performance evaluation of the Abbott Alinity hq hematology analyzer
  31. Cardiovascular Diseases
  32. Fast 0/1-h algorithm for detection of NSTEMI: are current high-sensitivity cardiac troponin assays fit for purpose? An EQA-based evaluation
  33. Infectious Diseases
  34. Diagnostic performance of cerebrospinal fluid free light chains in Lyme neuroborreliosis – a pilot study
  35. Letters to the Editor
  36. Quality management at the national biobanking level – establishing a culture of mutual trust and support: the BBMRI.at example
  37. Molecular diagnosis of MODY3 permitted to reveal a de novo 12q24.31 deletion and to explain a complex phenotype in a young diabetic patient
  38. Increased C-reactive protein values in the absence of inflammation: monoclonal immunoglobulin interference in immunonephelometry
  39. An approach based on simulated hemolysis for establishing the hemolysis index threshold for high-sensitivity cardiac troponin T assay
  40. Utility of the icteric index for the management of bilirubin test requesting
  41. Quality control of monocyte volume and distribution width parameters of the Beckman Coulter DxH series
  42. Mozhaisk haemoglobin variant effects on leukocyte differential channel using the Sysmex XN series
  43. Detection of a novel hemoglobin variant Hb Liaoning by matrix assisted laser desorption/ionization-time of flight mass spectrometry
  44. Appropriateness of repetitive therapeutic drug monitoring and laboratory turnaround time
  45. Congress Abstracts
  46. 51th National Congress of the Italian Society of Clinical Biochemistry and Clinical Molecular Biology (SIBioC – Laboratory Medicine)
https://doi.org/10.1515/cclm-2019-0023
Schlagwörter für diesen Artikel
cholesterol esterification; interleukin-6 (IL-6); liver transplantation; model of end-stage liver disease (MELD) score

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. The re-emergence of dried blood spot sampling – are we ready?
  4. Review
  5. The role of platelets in bleeding in patients with thrombocytopenia and hematological disease
  6. Opinion Paper
  7. Exertional hematuria: definition, epidemiology, diagnostic and clinical considerations
  8. Guidelines and Recommendations from Scientific Societies
  9. A protocol for testing the stability of biochemical analytes. Technical document
  10. Genetics and Molecular Diagnostics
  11. Hereditary hyperferritinaemia-cataract syndrome (HHCS) – an underestimated condition: ferritin light chain variant spectrum in German families
  12. General Clinical Chemistry and Laboratory Medicine
  13. Performance of a web-based application measuring spot quality in dried blood spot sampling
  14. Clinical application of a dried blood spot assay for sirolimus and everolimus in transplant patients
  15. Plasma and dried blood spot lysosphingolipids for the diagnosis of different sphingolipidoses: a comparative study
  16. Liquid biopsy of cerebrospinal fluid identifies neuronal pentraxin receptor (NPTXR) as a biomarker of progression of Alzheimer’s disease
  17. Integrity of serum samples is changed by modified centrifugation conditions
  18. Heparin and citrate additive carryover during blood collection
  19. Copeptin – a biomarker of short-term mortality risk (7 days) in patients with end-stage liver disease
  20. Comparison of a new rapid method for the determination of adalimumab serum levels with two established ELISA kits
  21. Measurement of α-dicarbonyl compounds in human saliva by pre-column derivatization HPLC
  22. Establishment of the intelligent verification criteria for a routine urinalysis analyzer in a multi-center study
  23. Reference Values and Biological Variations
  24. A new indirect estimation of reference intervals: truncated minimum chi-square (TMC) approach
  25. EGFR and EGFR ligands in serum in healthy women; reference intervals and age dependency
  26. Early pregnancy reference intervals; 29 serum analytes from 4 to 12 weeks’ gestation in naturally conceived and uncomplicated pregnancies resulting in live births
  27. Paediatric reference intervals for 17 Roche cobas 8000 e602 immunoassays in the CALIPER cohort of healthy children and adolescents
  28. Hematology and Coagulation
  29. Study of the analytical performance at different concentrations of hematological parameters using Spanish EQAS data
  30. Multicenter performance evaluation of the Abbott Alinity hq hematology analyzer
  31. Cardiovascular Diseases
  32. Fast 0/1-h algorithm for detection of NSTEMI: are current high-sensitivity cardiac troponin assays fit for purpose? An EQA-based evaluation
  33. Infectious Diseases
  34. Diagnostic performance of cerebrospinal fluid free light chains in Lyme neuroborreliosis – a pilot study
  35. Letters to the Editor
  36. Quality management at the national biobanking level – establishing a culture of mutual trust and support: the BBMRI.at example
  37. Molecular diagnosis of MODY3 permitted to reveal a de novo 12q24.31 deletion and to explain a complex phenotype in a young diabetic patient
  38. Increased C-reactive protein values in the absence of inflammation: monoclonal immunoglobulin interference in immunonephelometry
  39. An approach based on simulated hemolysis for establishing the hemolysis index threshold for high-sensitivity cardiac troponin T assay
  40. Utility of the icteric index for the management of bilirubin test requesting
  41. Quality control of monocyte volume and distribution width parameters of the Beckman Coulter DxH series
  42. Mozhaisk haemoglobin variant effects on leukocyte differential channel using the Sysmex XN series
  43. Detection of a novel hemoglobin variant Hb Liaoning by matrix assisted laser desorption/ionization-time of flight mass spectrometry
  44. Appropriateness of repetitive therapeutic drug monitoring and laboratory turnaround time
  45. Congress Abstracts
  46. 51th National Congress of the Italian Society of Clinical Biochemistry and Clinical Molecular Biology (SIBioC – Laboratory Medicine)
Jetzt anmelden und 20% sparen
Institutioneller Zugang
Wie funktioniert Authentifizierung?
Haben Sie eine Idee, wie wir unsere Website verbessern können?
Bitte schreiben Sie uns.
© 2025 De Gruyter Brill
Heruntergeladen am 9.11.2025 von https://www.degruyterbrill.com/document/doi/10.1515/cclm-2019-0023/html
Button zum nach oben scrollen